CN1426472A - 编码源于肝炎病毒orf2n端区域的加工组分以及抗原性多肽的核酸构建体 - Google Patents

编码源于肝炎病毒orf2n端区域的加工组分以及抗原性多肽的核酸构建体 Download PDF

Info

Publication number
CN1426472A
CN1426472A CN01808764A CN01808764A CN1426472A CN 1426472 A CN1426472 A CN 1426472A CN 01808764 A CN01808764 A CN 01808764A CN 01808764 A CN01808764 A CN 01808764A CN 1426472 A CN1426472 A CN 1426472A
Authority
CN
China
Prior art keywords
nucleic acid
processing component
seq
antigenic polypeptide
processing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01808764A
Other languages
English (en)
Chinese (zh)
Inventor
李凡
D·A·安德森
D·F·J·波塞尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Original Assignee
Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macfarlane Burnet Institute for Medical Research and Public Health Ltd filed Critical Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Publication of CN1426472A publication Critical patent/CN1426472A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/28011—Hepeviridae
    • C12N2770/28111—Hepevirus, e.g. hepatitis E virus
    • C12N2770/28122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CN01808764A 2000-03-31 2001-03-30 编码源于肝炎病毒orf2n端区域的加工组分以及抗原性多肽的核酸构建体 Pending CN1426472A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ6616 2000-03-31
AUPQ6616A AUPQ661600A0 (en) 2000-03-31 2000-03-31 A nucleic acid construct and methods related thereto

Publications (1)

Publication Number Publication Date
CN1426472A true CN1426472A (zh) 2003-06-25

Family

ID=3820712

Family Applications (1)

Application Number Title Priority Date Filing Date
CN01808764A Pending CN1426472A (zh) 2000-03-31 2001-03-30 编码源于肝炎病毒orf2n端区域的加工组分以及抗原性多肽的核酸构建体

Country Status (14)

Country Link
US (1) US7341723B2 (enExample)
EP (1) EP1274851B1 (enExample)
JP (1) JP2003528614A (enExample)
KR (1) KR100768051B1 (enExample)
CN (1) CN1426472A (enExample)
AT (1) ATE430804T1 (enExample)
AU (1) AUPQ661600A0 (enExample)
CA (1) CA2407036A1 (enExample)
DE (1) DE60138612D1 (enExample)
HK (1) HK1052368A1 (enExample)
MX (1) MXPA02009437A (enExample)
NZ (1) NZ521758A (enExample)
WO (1) WO2001073078A1 (enExample)
ZA (1) ZA200207769B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101189B2 (en) 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
DK1523329T3 (da) 2002-07-05 2013-10-14 Folia Biotech Inc Viruspartikeladjuvant
KR100641810B1 (ko) * 2004-04-23 2006-11-06 주식회사 포스코건설 충격흡수 및 복원 가능한 중간 스프링 설치 금속재 지주
US8906862B2 (en) 2009-02-27 2014-12-09 The Regents Of The University Of California Multiple antigen delivery system using hepatitis E virus-like particle
WO2010099547A1 (en) * 2009-02-27 2010-09-02 The Regents Of The University Of California Multiple antigen delivery system using hepatitis e virus-like particle
US8906863B2 (en) 2009-02-27 2014-12-09 The Regents Of The University Of California Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector

Also Published As

Publication number Publication date
ATE430804T1 (de) 2009-05-15
ZA200207769B (en) 2004-02-10
JP2003528614A (ja) 2003-09-30
WO2001073078A1 (en) 2001-10-04
NZ521758A (en) 2004-05-28
EP1274851B1 (en) 2009-05-06
KR100768051B1 (ko) 2007-10-18
EP1274851A1 (en) 2003-01-15
MXPA02009437A (es) 2006-05-25
CA2407036A1 (en) 2001-10-04
AUPQ661600A0 (en) 2000-05-04
US7341723B2 (en) 2008-03-11
KR20030015223A (ko) 2003-02-20
EP1274851A4 (en) 2004-12-08
HK1052368A1 (zh) 2003-09-11
DE60138612D1 (de) 2009-06-18
US20030158138A1 (en) 2003-08-21

Similar Documents

Publication Publication Date Title
US8445663B2 (en) Compositions and methods that enhance an immune response
CN1175260A (zh) 细胞毒t淋巴细胞应答的诱导
JP2016501850A (ja) 口蹄疫（ｆｍｄ）に対する合成ペプチドベースの緊急ワクチン
Mingxiao et al. Immunogenicity of plasmids encoding P12A and 3C of FMDV and swine IL-18
EP4126028A1 (en) Compositions and methods for treating and preventing coronaviruses
US20250057946A1 (en) Use of interferon as an adjuvant in vaccines
US20250127873A1 (en) Compositions and methods for prevention of piscine myocarditis
CN1426472A (zh) 编码源于肝炎病毒orf2n端区域的加工组分以及抗原性多肽的核酸构建体
US20220193224A1 (en) Rsv-based virus-like particles and methods of production and use thereof
CN1047531A (zh) 猪瘟病毒疫苗和诊断
WO2024209218A1 (en) Coronavirus vaccines inducing broad immunity against variants
CN100335637C (zh) 采用丙型肝炎病毒非结构蛋白进行的基因免疫
CN1717416A (zh) 丙型肝炎病毒非结构蛋白4a(ns4a)是增强子元件
CN1791427A (zh) 预防和治疗sars的新型疫苗的设计方法及其成分
AU2001243941B2 (en) A nucleic acid construct encoding a processing component derived from the n-terminal region of the hepatitis virus ORF2, and an antigenic polypeptide
US20250057937A1 (en) Compositions and methods for expressing antigens on cell membrane
CN1772892A (zh) Hiv－1病毒样颗粒及其制备方法与用途
US20230295244A1 (en) Compositions and methods for treating and preventing coronaviruses
CN1751064A (zh) 节杆菌来源的hsp60
CN1324139C (zh) 疫苗
US20160215023A1 (en) Simple vaccines from dna launched suicidal flaviviruses
AU2001243941A1 (en) A nucleic acid construct encoding a processing component derived from the n-terminal region of the hepatitis virus ORF2, and an antigenic polypeptide
CN1927881A (zh) 一种多聚肽、其制备方法、包含它的药物组合物和疫苗及其用途
HK1165694B (en) Codon-optimized hepatitis b virus core antigen (hbcag)
HK1098952A (en) Antigen delivery system

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication